Physician profile

Lori Maciulla

Gynecology · Mc Lean, VA

NPI 1528079837

$486.72

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$157.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $115.67 2023
Aspira Women'S Health INC $86.63 2021-2023 Ova1
Pfizer INC. $79.46 2019-2023
Mayne Pharma Commercial LLC $62.88 2022
Abbvie INC. $47.84 2021-2022
Renovia INC $23.54 2021
Scynexis, INC. $18.49 2022
Exeltis, USA INC. $18.23 2022
Hologic Sales and Service, LLC $17.69 2021
Astellas Pharma US INC $16.29 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lori Maciulla

$486.72

in general payments reported 2019-2025

Years
2019-2023
Top company
Takeda Pharmaceuticals U.S.A., INC.

https://glasscript.com/doctor/947644/lori-maciulla

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.